CHB patients with rtA181T ‐mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes
Journal of Viral Hepatitis · 2023-12 · 30 (12) · 951-958
DOI: 10.1111/jvh.13886 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 21.09.2023. Verfasst von Qiqi Ning und 10 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Hepatology, Beijing You An Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hepatitis B, Chronic, Liver Neoplasms. Die Arbeit wurde bisher 203-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Capital Health Research and Development Special grants, Chinesisch-Deutsches Forschungsprojekt im Sonderprogramm zu COVID-19 (C-0012) and Key Programs of Beijing Municipal Education Commission of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
The HBV rtA181T mutation is associated with an increased risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study aimed to evaluate the mechanism by which rtA181T mutation increases the risk of HCC. We enrolled 470 CHB patients with rtA181T and rtA181V mutation in this study; 68 (22.15%) of the 307 patients with rtA181T mutation and 22 (13.5%) of the 163 patients with rtA181V mutation developed HCC ( p < .05). The median follow‐up periods were 8.148 and 8.055 years ( p > .05). Serum HBV DNA and HBsAg levels in rtA181T‐positive patients were similar to that in rtA181V‐positive patients. However, the serum HBeAg levels in the rtA181T‐positive patients were significantly higher than that in rtA181V‐positive patients. In situ hybridization experiments showed that the HBV cccDNA and HBV RNA levels were significantly higher in the liver cancer tissues of patients with the rtA181T mutation compared to that in the tissues of patients with the rtA181V mutation. The percentage of anti‐tumour hot‐gene site mutations was significantly higher in the rtA181T‐positive HCC liver tissue compared to that in the rtA181T‐negative HCC liver tissue (7.65% and 4.3%, p < .05). This is the first study to use a large cohort and a follow‐up of more than 5 years (average 8 years) to confirm that the rtA181T mutation increased the risk of HCC, and that it could be related to the increase in the mutation rate of hotspots of tumour suppressor genes (CTNNB1, TP53, NRAS and PIK3CA).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Institute of Hepatology, Beijing You An Hospital, Capital Medical University, Beijing, China.
- Beijing Precision Medicine and Transformation Engineering Technology Research Center of Hepatitis and Liver Cancer, Beijing, China.
- Academician Workstation, Changsha Medical University, Changsha, China.
- Hunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, China.
- Clinical laboratory center, Beijing You An Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Dexi Chen
Förderung
- Capital Health Research and Development Special grants
- Chinesisch-Deutsches Forschungsprojekt im Sonderprogramm zu COVID-19 (C-0012) and Key Programs of Beijing Municipal Education Commission of China
- National Key Research and Development Program of China
- Third Round of Public Welfare Development and Reform Pilot Projects of Beijing Municipal Medical Research Institutes
- National Basic Research Program of China
Zitieren
APA
Ning, Q., Yang, T., Guo, X., Huang, Y., Gao, Y., Liu, M., Yang, P., Guan, Y., Liu, N., Wang, Y., & Chen, D. (2023). CHB patients with rtA181T ‐mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes. Journal of Viral Hepatitis, 30(12), 951-958. https://doi.org/10.1111/jvh.13886
Vancouver
Ning Q, Yang T, Guo X, Huang Y, Gao Y, Liu M, et al. CHB patients with rtA181T ‐mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes. Journal of Viral Hepatitis. 2023;30(12):951-958. doi:10.1111/jvh.13886
BibTeX
@article{Ning2023,
author = {Ning, Qiqi and Yang, Tongwang and Guo, Xianghua and Huang, Yanxiang and Gao, Yuxue and Liu, Mengcheng and Yang, Pengxiang and Guan, Yuanyue and Liu, Ning and Wang, Yang and Chen, Dexi},
title = {CHB patients with rtA181T ‐mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes},
journal = {Journal of Viral Hepatitis},
year = {2023},
volume = {30},
number = {12},
pages = {951--958},
doi = {10.1111/jvh.13886}
}
EUVIMED